Walvax Biotechnology (300142.SZ) Earnings Analysis
Walvax Biotechnology (300142.SZ) next reports earnings on 2026-08-29, consensus EPS 0.11 CNY. Last quarter (2026-04-24) it beat with EPS 0.07 CNY vs 0.02 CNY est (+250%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E 74.24.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 300142.SZ next report earnings?
| Next earnings date | 2026-08-29 |
|---|---|
| Consensus EPS estimate | 0.11 CNY |
| Revenue estimate | 0.70B |
300142.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-24 | 0.07 CNY | 0.02 CNY | +250% | Beat |
| 2026-03-28 | 0.01 CNY | 0.04 CNY | -75% | Miss |
| 2025-04-25 | -0.07141 CNY | 0.05 CNY | -242.8% | Miss |
| 2025-04-11 | -0.07 CNY | -0.06 CNY | -16.7% | Miss |
| 2024-10-25 | 0.05 CNY | 0.06 CNY | -16.7% | Miss |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
300142.SZ valuation and analyst view
| Trailing P/E | 74.24 |
|---|---|
| Trailing EPS | 0.17868 CNY |
| Price / book | 2.86 |
| Dividend yield | 1.17% |
| Market cap | 21.58B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Walvax Biotechnology (300142.SZ)'s next earnings date?
Walvax Biotechnology is next scheduled to report on 2026-08-29, with a consensus EPS estimate of 0.11 CNY and revenue estimate of 0.70B.
Did 300142.SZ beat earnings last quarter?
In its 2026-04-24 report, 300142.SZ posted EPS of 0.07 CNY versus a 0.02 CNY estimate — a beat of 250%.
What is 300142.SZ's earnings track record?
Over the last 5 reported quarters with consensus data, 300142.SZ beat estimates 1 times (20%).
What is 300142.SZ's current P/E ratio and EPS?
300142.SZ trades at a trailing P/E of 74.24 on trailing EPS of 0.17867706247018628 CNY.
What do analysts rate 300142.SZ?
300142.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.